Grants and Contributions:
Title:
Preclinical Development of Apelin Analog and Completion of Regulatory Procedures
Agreement Number:
939480
Agreement Value:
$140,000.00
Agreement Date:
Jan 1, 2020 - Mar 31, 2021
Description:
PEARKO Therapeutics’s apelin analog will be synthesized by Bachem, a Good Manufacturing Practices (GMP)-certified producer of peptides for clinical use. We will use study findings to optimize intravenous and subcutaneous formulations of our biologic, and scale-up production. Over the same period, regulatory filings will be completed for Health Canada, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to augment the clinical trial process and international market entry. Completion of these steps will allow PEARKO Therapeutics to proceed through the final stages of preclinical development and complete the Investigational New Drug application, mandated by the FDA, in anticipation of Phase I clinical trials in 2022.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T6R 3A5
Reference Number:
172-2019-2020-Q4-939480
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
824764641
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 140,000 dollars.
Amendment Date
Feb 28, 2020
Recipient's Legal Name:
PEARKO Therapeutics Inc.
Federal Riding Name:
Edmonton Riverbend
Federal Riding Number:
48018
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: